Slide 1: Fourth Quarter and Full Year 2025 Financial Results
Fourth Quarter and Full Year 2025 Financial Results March 16, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements regarding Kyntra Bio’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its partners Fortis and UCSF. These forward-looking statements inclu
Slide 3: Investment Highlights
Investment Highlights Transformed into Kyntra Bio: Creating Outsized Impact for Patients and Shareholders • Completed sale of FibroGen China to AstraZeneca for approximately $220 million • Successfully repaid term loan to Morgan Stanley Tactical Value, further simplifying capital structure • Extende
Slide 4: FG-3246 & FG-3180 Program
Kynira BIO FG-3246 & FG-3180 Program
Slide 5: Prostate Cancer Has a High Unmet Need for Treatment Options That Extend Survival in Late-Stage Disease
Prostate Cancer Has a High Unmet Need for Treatment Options That Extend Survival in Late-Stage Disease Prostate cancer is the second ~ 65,000 drug treatable mCRPC most common cancer type cases in the U.S. annually of men will be diagnosed with prostate 13% cancer at some point during their lifetime
Slide 6: CD46 as a Novel Tumor Selective Target in Solid Tumors
CD46 as a Novel Tumor Selective Target in Solid Tumors CD46 negatively regulates the complement system and helps tumors evade complement-dependent cytotoxicity Negatively regulates the complement system and helps tumors evade complement- dependent cytotoxicity CD46 A part of a protein complex mediat
Slide 7: Targeting a Novel Epitope of CD46 Has Therapeutic and Diagnostic Potential
Targeting a Novel Epitope of CD46 Has Therapeutic and Diagnostic Potential FG-3246 FG-3180 PET Therapeutic Imaging Agent Targeting antibody + Payload Targeting antibody +89Zr tracer MMAE: a potent anti-microtubule YS5 is a fully-human, full length, Demonstrated specific uptake in CD46 agent (validat
Slide 8: Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in mCRPC
Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in mCRPC Key inclusion criteria Study endpoints • Progressive mCRPC per PCWG3 criteria • Primary Endpoint for Phase 1b: Determine maximally tolerated dose (MTD) • Progressed on at least 1 prior androgen-signaling inhibitor and recommended
Slide 9: Encouraging Anti-Tumor Activity Observed in the Phase 1b/2 Study of FG-3246 with Enzalutamide
Encouraging Anti-Tumor Activity Observed in the Phase 1b/2 Investigator-Initiated Study of FG-3246 in Combination with Enzalutamide in mCRPC Phase 1b/2 results in biomarker unselected patients, Phase 1b/2 results in patients who progressed majority of who progressed on ≥2 prior ARPIs on 1 prior ARPI
Slide 10: Higher Tumor Uptake of FG-3180 (PET46) was Associated with PSA50 Response
Higher Tumor Uptake of FG-3180 (PET46) was Associated with PSA50 Response PSA50 Response P-value Yes (n=7) No (n=16) 11.68 9.24 SUVmax-ave [9.91-13.88] [7.98-10.64] 0.109 9.57 7.58 SUVmax-ave/ SUVmean blood pool [9.24-11.93] [6.66-9.80] 0.053 Results demonstrate FG-3180’s potential as PET imaging bi
Slide 11: FG-3246 + Enzalutamide Combination Safety Profile Consistent with FG-3246 Monotherapy
FG-3246 + Enzalutamide Combination Safety Profile Consistent with FG-3246 Monotherapy TRAEs Summary Evaluable patients (n=41) n (%) Any grade 41 (100) Grade ≥ 3 9 (22.) Serious TRAEs 3 (7.3) Leading to death 0 (0) Leading to FG-3246 15 (36.6) discontinuation • Neutropenia risk was successfully mitig
Slide 12: FG-3246 Demonstrated Meaningful Monotherapy Clinical Activity in 5L+ mCRPC Patients
FG-3246 Demonstrated Meaningful Monotherapy Clinical Activity in 5L+ mCRPC Patients Phase 1 dose escalation and expansion study results in biomarker unselected and heavily pre-treated patient population with median of 5 prior lines of therapy Efficacy analysis included 40 patients from the 8.7 7.5 d
Slide 13: FG-3246 and FG-3180 Phase 2 Monotherapy Trial Initiated
FG-3246 and FG-3180 Phase 2 Monotherapy Trial Initiated Interim results expected in 2H 2026 Phase 2 - FG-3246 Dose Optimization in Post-ARPI, Pre-Chemo mCRPC, All Comers (US only) Primary Endpoint: Optimal dose for Phase 3 based on efficacy, safety, and PK Expected Secondary Endpoints: rPFS, PSA50,
Slide 14: FG-3246 Phase 2 Monotherapy Trial: Three Main Design Elements
FG-3246 Phase 2 Monotherapy Trial: Three Main Design Elements Driving the Potential for Increasing rPFS versus the Phase 1 Study (>8.7 months) Further validated by Phase 1b/2 Combination IST Use of three of the Use of primary Moving upline to patients highest doses (1.8mg/kg; prophylaxis G-CSF to wh
Slide 15: FG-3246 Program Recent & Upcoming Catalysts
FG-3246 Program Recent & Upcoming Catalysts 2Q 2025 3Q 2025 1Q 2026 2H 2026 FG-3180 IND Initiated Phase 2 FG- Topline results from the Interim analysis from Clearance 3246 monotherapy trial, investigator sponsored study Phase 2 FG-3246 of FG-3246 + enzalutamide including FG-3180 monotherapy trial •
Slide 16: FG-3246 and FG-3180 Present Unique Opportunity in mCRPC
FG-3246 and FG-3180 Present Unique Opportunity in mCRPC Compelling Results in Two Phase 1 Studies FG-3246 was clinically active as monotherapy and in combination with enzalutamide Novel Mechanism of Action and Potential Consistent Safety Profile First-in-Class Opportunity Adverse events consistent w
Slide 17: Roxadustat Program
Kynira BIO Roxadustat Program
Slide 18: Anemia Associated with Lower-Risk MDS Represents a Significant Opportunity
Anemia Associated with Lower-Risk MDS Represents a Significant Opportunity Anemia is the hallmark symptom of MDS that gives rise to significant morbidity ~75K patients live with MDS in the U.S. Prevalence, United 58K States, 2022 Patients are ~90% suffering from anemia and its 75K LR-MDS negative im
Slide 19: Anemia of LR-MDS: Phase 3 Development Opportunity Based on Post Hoc Subgroup Results from MATTERHORN
Anemia of LR-MDS: Phase 3 Development Opportunity Based on Post Hoc Subgroup Results from MATTERHORN Phase 3 Trial In patients with high transfusion burden1, roxadustat showed promising TI benefits compared to placebo No. of patients with Roxadustat Placebo 8-wk RBC TI 8-wk RBC TI response (% [95% C
Slide 20: Roxadustat May Elevate the Standard of Care in 2L+ LR-MDS-Anemia
Roxadustat May Elevate the Standard of Care in 2L+ LR-MDS-Anemia Target indication: Treatment of anemia in Del(5q) (~10%) RS+ RS- (30-40%) (50-60%) patients with LR-MDS and 1L Lenalidomide Luspatarcept ESA1 HTB who are refractory to, Luspatercept intolerant to, or ineligible for, prior ESA treatment
Slide 21: Potential Pivotal Phase 3 Trial Overview
Potential Pivotal Phase 3 Trial Overview Currently exploring the opportunity to develop internally or with a strategic partner Patient Population Safety • High transfusion burden: Patients requiring ≥ 4 pRBC Management of potential thrombotic risk through: units in two consecutive 8-week periods pri
Slide 22: Significant Opportunity for Roxadustat in Anemia Associated with LR-MDS
Significant Opportunity for Roxadustat in Anemia Associated with LR-MDS Substantial • Significant unmet need despite recent approvals unmet need in LR-MDS anemia • No other oral treatments for anemia of LR-MDS commercially available or in late-stage development • Differentiated profile with potentia
Slide 23: Financial Results
Kynira BIO Financial Results
Slide 24: Thank You
Thank You For more information contact ir@kyntrabio.com NASDAQ: KYNB